1	PETER M. BRODY (pro hac vice)	JOSEPH E. CWIK (pro hac vice)	
	MARK S. POPOFSKY(CSB # 175476)	UPADHYE CWIK LLP	
2	ROPES & GRAY LLP 2099 Pennsylvania Avenue, NW	135 S LaSalle St. Suite 1930	
3	Washington, DC 20006-6807	Chicago, IL 60603 Tel: 312.598.2610	
4	Tel: 202-508-4600 Fax: 202-508-4650	joe@ipfdalaw.com	
	peter.brody@ropesgray.com	J	
5		BENJAMIN L. ENGLAND (pro hac vice)	
6	DAVID S. CHUN (CSB # 315958) ROPES & GRAY LLP	JESSICA R. RIFKIN (pro hac vice)	
_	1900 University Avenue	BENJAMIN L. ENGLAND & ASSOCIATES, LLC	
7	East Palo Alto, CA 94303-2284 Tel: 650-617-4000	810 Landmark Drive, Suite 126	
8	Fax: 650-617-4090	Glen Burnie, MD 21061	
9	david.chun@ropesgray.com	Tel: (410) 220-2800	
9	ANNE JOHNSON PALMER (CSB #	Fax: (443) 583-1464	
10	302235)	blengland@fdaimports.com	
11	ROPES & GRAY LLP Three Embarcadero Center	jrrifkin@fdaimports.com	
	San Francisco, CA 94111-4006		
12	Tel: 415-315-6300 Fax: 415-315-6350	Attorneys for Defendant,	
13	anne.johnsonpalmer@ropesgray.com	ECI PHARMACEUTICALS LLC	
14 15	Attorneys for Plaintiff, BAUSCH HEALTH US, LLC		
16			
17	UNITED STATES DISTRICT COURT		
18	NORTHERN DISTRICT OF CALIFORNIA SAN FRANCISCO DIVISION		
19		Jeo Division	
	BAUSCH HEALTH US, LLC,	C N- 10 CV 00255 DC	
20	Plaintiff,	Case No. 18-CV-00355-RS	
21	V.		
22		STIPULATION AND [PROPOSED]	
	ECI PHARMACEUTICALS LLC,	ORDER CONCERNING MODIFICATION	
23	Defendant.	OF SCHEDULING ORDER	
24			
25		_	
26			
27			
28			
-	I		

Pursuant to Civil Local Rule 6-2, 7-1(a)(5), and 7-12, Defendant ECI Pharmaceuticals LLC ("ECI") and Plaintiff Bausch Health US, LLC ("Bausch") (jointly, the "Parties"), by and through their respective counsel, hereby stipulate as follows:

WHEREAS the following time modifications have been previously made in this case:

A thirty (30) day extension of time, until January 19, 2018, for Defendant to file a Rule 12 motion, answer, or otherwise respond to the complaint in Plaintiff's originally-filed action against Defendant and other parties (Dkt. 21; Chun Declaration in Support of Stipulation and Proposed Order ("Chun Decl."), ¶ 5);

A further extension of Defendant's deadline to file a responsive pleading until twenty-one (21) days after Plaintiff filed its amended complaint in this severed action, which was so Ordered by the Court on January 16, 2018 (Dkt. 34; Chun Decl. ¶ 6);

A further extension of time permitting Plaintiff an extension of time to file its Opposition to Defendant's Rule 12 Motion filing and Defendant an extension of time to file its Reply to March 27, 2018 and April 24, 2018, respectively (Dkt. 40; Chun Decl. ¶ 9);

A stay of the case from May 4, 2018 to July 31, 2018 pursuant to 28 U.S.C. § 1659(a) pending the determination or termination of ITC Investigation No. 337-TA-1109, captioned "In the Matter of Certain Clidinium Bromide and Products Containing Same" (Dkts. 70, 72; Chun Decl. ¶ 11);

A modification of the schedule setting the deadline for the Defendant to file its Reply in Support of its Motion to Dismiss for October 12, 2018 and setting a Joint Hearing on the Motion to Dismiss for October 25, 2018 (Dkt. 79; Chun Decl. ¶ 12);

A modification of the schedule setting the deadline for Plaintiff to answer Defendant's counterclaims and further modify the scheduling order (Dkt. 102) with respect to fact and expert discovery deadlines (Dkt. 136);

WHEREAS the Parties submitted to this Court under seal on January 9, 2020 a Joint Letter Brief Regarding Certain Discovery Disputes ("Joint Letter");

WHEREAS the discovery disputes raised in the Parties' Joint Letter were referred to Magistrate Judge Kandis A. Westmore on January 15, 2020 and remain pending;

WHEREAS Defendant has indicated it intends to amend its pleadings on or before February 7, 2020, pursuant to the Court's Further Case Management Scheduling Order (Dkt. 150):

WHEREAS the Parties are engaged in active settlement discussions;

WHEREAS the Parties further agree to modify the current scheduling order (Dkt. 102, as modified by Order Dkt. 136) as follows:

Event	Current Date	Proposed Date
Close of all non-expert discovery	January 31, 2020	February 28, 2020
Designation of experts in accordance with FRCP 26(a)(2)	February 14, 2020	March 13, 2020
Designation of supplemental and rebuttal experts in accordance with FRCP 26(a)(2)	March 27, 2020	April 17, 2020
Completion of all discovery of expert witnesses pursuant FRCP 26(b)(4)	May 8, 2020	No Change
Further Case Management Conference	January 16, 2020 at 10:00am	No Change
Deadline for hearing of all pretrial motions	July 2, 2020	No Change
Pretrial Conference	On or about September 2, 2020 at 10:00am	No Change
Jury Trial Commences	Beginning on or after September 28, 2020 at 9:00 am	No Change

WHEREAS the Parties believe that good cause exists for these extensions so that the parties can meet their discovery obligations, prepare for depositions, and continue settlement efforts, while leaving the existing trial date and remaining deadlines unaffected;

WHEREAS the Parties do not believe that these proposed time modifications would have any detrimental effect on the schedule for the case, or would cause prejudice to any party;

1	Benjamin L. England (pro hac vice)
2	Jessica R. Rifkin (<i>pro hac vice</i>) BENJAMIN L. ENGLAND & ASSOCIATES,
3	LLC 810 Landmark Drive, Suite 126
4	Glen Burnie, MD 21061
5	Tel: (410) 220-2800 Fax: (443) 583-1464
6	<u>blengland@fdaimports.com</u> <u>jrrifkin@fdaimports.com</u>
7	Counsel for Defendant
8	ECI Pharmaceuticals, LLC
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	

[PROPOSED] ORDER

PURSUANT TO STIPULATION, IT IS SO ORDERED.

Dated: 1/23 , 2020.

Honorable Richard Seeborg

United States District Judge